Prostate cancer: Advances in immunotherapy

Arthur A. Hurwitz, Paul Yanover, Mary Markowitz, James P. Allison, Eugene D. Kwon

Research output: Contribution to journalReview article

17 Scopus citations

Abstract

The absence of curative therapies for advanced or recurrent forms of prostate cancer has prompted a vigorous search for novel treatment strategies. Immunotherapy encompasses one particularly promising systemic approach to the treatment of prostate cancer. Immune-based strategies for treating prostate cancer have recently been facilitated by the identification of a number of prostate tissue/tumour antigens that can be targeted, either by antibody or T cells, to promote prostate tumour cell injury or death. These same prostate antigens can also be used for the construction of vaccines to induce prostate-specific T cell-mediated immunity. Greater insight into specific mechanisms that govern antigen-specific T cell activation has brought with it a number of innovative methods to induce and enhance T cell-mediated responses against prostate tumours. For instance, autologous dendritic cells loaded with prostate antigens have proved useful to induce prostate-specific T cell activation. Similarly, in vivo manipulations of T cell costimulatory pathway receptors can greatly facilitate tumour-specific T cell activation and potentiate T cell-mediated responses against a number of malignancies, including prostate cancer. For example, blocking T cell cytotoxic lymphocyte-associated antigen 4 (CTLA-4) receptor binding to its ligand prevents the down-regulation of T cell responses and can even potentiate T cell antitumoural immunity in mouse models of prostate cancer. Androgen ablation (AA) may induce prostate tumour/tissue-specific T cell mediated inflammation and, as such, a phase II trial is currently in progress to ascertain whether CTLA-4 blockade can enhance AA-induced treatment responses in patients with advanced prostate cancer. Nevertheless, further basic and clinical investigation is still required to establish immunotherapy as a true prostate cancer treatment option.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalBioDrugs
Volume17
Issue number2
DOIs
StatePublished - Apr 24 2003

ASJC Scopus subject areas

  • Biotechnology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Prostate cancer: Advances in immunotherapy'. Together they form a unique fingerprint.

  • Cite this

    Hurwitz, A. A., Yanover, P., Markowitz, M., Allison, J. P., & Kwon, E. D. (2003). Prostate cancer: Advances in immunotherapy. BioDrugs, 17(2), 131-138. https://doi.org/10.2165/00063030-200317020-00005